Generation of TIM3 inhibitory single‑domain antibodies to boost the antitumor activity of chimeric antigen receptor T cells
Authors:
Open Access
- 20 May 2021
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 22 (1) , 1-11
Abstract
Targeting inhibitory immune checkpoint molecules has significantly altered cancer treatment regimens. T cell immunoglobulin and mucin domain 3 (TIM3) is one of the major inhibitory immune checkpoints expressed on T cells. Blocking the engagement of TIM3 and its inhibitory ligand galectin‑9 may potentiate the effects of immunotherapy or overcome the adaptive resistance to the therapeutic blockade of programmed cell death protein 1, cytotoxic T‑lymphocyte‑associated protein 4, B‑ and T‑lymphocyte attenuator and lymphocyte‑activation gene 3, amongst others, as each of these immune checkpoints harbors unique properties that set it apart from the rest. Heavy chain variable fragment (VH)‑derived single‑domain antibodies (sdAbs) represent a class of expanding drug candidates. These sdAbs have unique advantages, including their minimal size in the antibody class, ease of expression, broad scope for modular structure design and re‑engineering, and excellent tumor penetration. In the present study, two sdAbs, TIM3‑R23 and TIM3‑R53, were generated by immunizing rabbits with the recombinant extracellular domain of TIM3 and applying phage display technology. These sdAbs were easily expressed in mammalian cells. The purified sdAbs were able to bind to both recombinant and cell surface TIM3, and blocked it from binding to the ligand galectin‑9. In vivo studies demonstrated that TIM3‑R53 was able to potentiate the antitumor activity of chimeric antigen receptor T cells that targeted mesothelin. In conclusion, the results of the present study suggested that TIM3‑R53 may be a novel and attractive immune checkpoint inhibitor against TIM3, which is worthy of further investigation.Keywords
This publication has 35 references indexed in Scilit:
- Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006British Journal of Cancer, 2018
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyThe Lancet Oncology, 2016
- Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activationJournal of Experimental Medicine, 2015
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Tim-3: An Activation Marker and Activation Limiter of Innate Immune CellsFrontiers in Immunology, 2013
- Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicityBlood, 2012
- Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune CellsScience, 2007
- The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunityNature Immunology, 2005
- Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene familyNature Immunology, 2001